Inositol for PCOS: Myo-Inositol vs D-Chiro, Dosage & The 40:1 Ratio Explained

Inositol for PCOS sits among the few supplement-aisle stories where the underlying biology and the trial literature genuinely line up — and yet the loudest claims about it still overshoot what the data actually shows. The strongest evidence is metabolic — modest improvements in fasting insulin and HOMA-IR across twelve to twenty-four weeks, with cycle-regulation gains trailing the metabolic ones. The weakest evidence, and the kind this article will not promise, is anything to do with becoming pregnant.

The compound itself is a pair of stereoisomers — myo-inositol and D-chiro-inositol — handling different jobs inside the insulin-signalling pathway, and the now-standard 40:1 ratio exists for a specific physiological reason rather than for a marketing one. What follows is what randomised controlled trials actually demonstrate, where the supplement industry overstates the picture, and how inositol stacks up against metformin, NAC and spearmint tea — the three other names that come up in nearly every PCOS supplement conversation. This is the inositol coverage inside the women's hormonal-balance supplement guide. It is intentionally a long read, because PCOS is a clinical diagnosis and supplement decisions around it deserve more than a 1,200-word listicle.

PCOS is a clinical diagnosis. Talk to your endocrinologist or OB-GYN before starting inositol or any PCOS supplement, especially if you are trying to conceive or on metformin/oral contraceptives.

This article is for informational purposes only and is not medical advice. Speak with a qualified healthcare provider before starting any new supplement, especially if you are pregnant, breastfeeding, taking medication, or managing a medical condition.

What inositol actually is — and why PCOS researchers care about it

Inositol itself is a small sugar alcohol with molecular formula C₆H₁₂O₆ — the same composition as glucose, but folded into a six-hydroxyl ring on a cyclohexane scaffold. Nine stereoisomers are possible; only two matter clinically for PCOS. Myo-inositol (MI) accounts for roughly 99% of the cellular inositol pool inside human cells and serves as the precursor to two second-messenger systems: inositol triphosphate (IP3), which sits downstream of FSH and TSH, plus a myo-inositol-containing inositol phosphoglycan (MI-IPG) involved in insulin's glucose-transport action. D-chiro-inositol (DCI) is an MI epimer; a tissue-specific epimerase, switched on by insulin, converts MI to DCI on demand. DCI-IPG then activates glycogen synthase. The two isomers do related but non-interchangeable work [unfer2017].

Inositol is not technically a vitamin, in spite of older labels marketing it as "vitamin B8": both the human body and the gut microbiota can synthesise it, while a typical Western diet supplies somewhere in the 500–1,000 mg per day range from citrus, cantaloupe, beans, brown rice and similar foods. The supplemental doses tested in PCOS, at 4 g per day, are several times that dietary baseline.

The reason inositol first caught the eye of PCOS researchers is that women with PCOS — particularly the insulin-resistant phenotypes — show a measurable defect in MI-to-DCI handling. Baillargeon and colleagues documented in 2006 that obese PCOS women carry an "uncoupling" between insulin signalling and DCI-IPG release, alongside urinary inositol clearance patterns that diverge from controls [baillargeon2006]. That mechanistic finding is what justifies lifting inositol off the shelf of small sugar alcohols and giving it serious trial attention as a dedicated PCOS supplement.

Myo-inositol vs D-chiro-inositol — and why the 40:1 ratio is not arbitrary

The number plastered across nearly every inositol product page is 2 grams of myo-inositol plus 50 milligrams of D-chiro-inositol, twice a day, working out to a 40-to-1 ratio. Before that number means much, two questions deserve answers: where the 40:1 actually came from, and why bumping the DCI higher is not the upgrade it looks like.

A 40:1 ratio reflects the plasma physiology of healthy fertile women. Across published measurements in non-PCOS controls, the circulating MI-to-DCI ratio hovers near 40:1; the working hypothesis from the Unfer / Facchinetti group is that supplying the supplement at the same ratio should restore the disrupted tissue equilibrium seen in PCOS [unfer2014]. The argument is not that 40:1 is therapeutically magical — it is that doses ratioed to physiology behave more predictably across phenotypes than doses ratioed to convenience.

Why higher DCI is not better has a name: the D-chiro-inositol paradox. Carlomagno, Unfer and Roseff flagged it in a 2011 short communication that pulled together trials in which DCI doses at or above roughly 1,200 mg per day produced worse oocyte quality in PCOS women undergoing IVF, even while peripheral metabolic markers kept improving [carlomagno2011]. The proposed mechanism: a PCOS-affected ovary is already MI-depleted because the peripheral epimerase is running hot, so pouring still more DCI into the system drains the MI pool that the follicle needs for FSH signalling. The clinical takeaway is unambiguous — avoid DCI-monotherapy products, particularly at the upper dose end. The 40:1 architecture exists precisely so that peripheral tissue gets enough DCI for its glycogen-synthase work without depleting ovarian MI.

The practical takeaway: myo-inositol-only formulations dosed at 4 g per day are still a perfectly reasonable choice, particularly for the leaner PCOS phenotype; the 40:1 blend is the better-studied combination once insulin resistance dominates the picture; and any "D-chiro-only" formulation is a red flag — either the manufacturer has not read Carlomagno 2011, or they are hoping the customer has not.

What the evidence actually shows — inositol for PCOS, by outcome

A useful frame before reading any individual trial: in 2024, Fitz and colleagues published their pooled analysis in the Journal of Clinical Endocrinology & Metabolism, feeding into the 2023 update of the International Evidence-Based PCOS Guidelines. Thirty trials and 2,230 participants were combined; the certainty of evidence for inositol's metabolic, hormonal and reproductive effects in PCOS was graded low to very low under GRADE methodology [monash2024]. The underlying trials are real. The direction of effect leans favourable. The safety signal is good. The honest qualification: as a body of evidence this still sits in "supportive nutrition adjunct" territory and is not first-line endocrine therapy.

Insulin sensitivity and HOMA-IR

This is where the case for inositol stands tallest. Greff and colleagues, writing in Reproductive Biology and Endocrinology in 2023, pooled 26 RCTs and reported a statistically significant drop in fasting insulin (mean difference about −2.8 μIU/mL) and HOMA-IR (mean difference about −0.40) compared with control [greff2023]. The older single-trial literature points the same way — Costantino 2009, Gerli 2007, Nordio 2012 and the 2019 Le Donne paper — with myo-inositol at 2 g twice daily over a 12-to-24-week window pushing fasting insulin downward in PCOS at effect sizes broadly comparable to a structured lifestyle intervention [costantino2009][nordio2012].

The Monash review's GRADE-low caveat still bites here: the individual trials are modest in size, inclusion criteria vary across them, and a handful were run unblinded. Inositol does appear to genuinely help insulin sensitivity. The strength of clinical recommendation that evidence base can carry, though, is moderate at best.

Menstrual cycle restoration and ovulation

Across multiple RCTs, ovulation returns in roughly 62–72% of MI-treated subjects with PCOS versus 46–52% in placebo arms over six-month windows [costantino2009][raffone2010]. Once the data were pooled, Greff 2023 also flagged a statistically significant gain in menstrual cycle frequency [greff2023]. The 2012 Cochrane review by Showell and colleagues, looking specifically at inositol in subfertility associated with PCOS, concluded that the data hint at possible clinical-pregnancy improvements but rated overall certainty at very low and declined to issue any strong clinical recommendation; the 2024 Monash re-analysis landed in essentially the same place [showell2012][monash2024].

Translated into something usable: many women on the 40:1 protocol see cycle shifts inside three to six menstrual cycles, the average direction is favourable, and a non-trivial minority do not respond at all. Predicting responder status from baseline labs is, for now, more aspiration than reality.

Androgen reduction (testosterone, SHBG)

Greff 2023 picked up a small but statistically significant drop in total testosterone for inositol versus control [greff2023]. The picture for SHBG — sex hormone binding globulin — is messier across trials, with some reporting a rise and others nothing. Clinical relevance for hirsutism and acne, both downstream of free androgen exposure, is plausible but unproven at trial durations under six months. Spearmint tea, covered further down, has stronger single-trial evidence on free testosterone specifically.

BMI and weight — frame honestly

"Best supplements for PCOS weight loss" ranks among the highest-volume PCOS searches, and the honest answer is that inositol is not a weight-loss supplement. A handful of trials report modest weight changes of one to two kilograms over six months, but those protocols almost always layer in concurrent dietary counselling and exercise prescription alongside [nordio2012]. The 2024 Monash review found no clinically meaningful weight effect attributable to inositol on its own [monash2024].

The honest framing is that inositol may improve insulin sensitivity, and better insulin sensitivity makes a calorie deficit easier to hold over the months it takes for body composition to shift. The supplement does not replace the deficit. For broader weight-management context this piece cross-links across to the women's weight-management supplement category, where fat-loss supplements are discussed honestly and the ones unsafe to stack with PCOS medication are flagged.

Why fertility outcome claims are off-limits in a consumer article

Published data does exist — including a body of IVF work from Papaleo and colleagues — suggesting inositol can improve oocyte quality and lower IVF cancellation rates in patients with PCOS. That body of evidence sits inside a clinical setting under a reproductive endocrinologist's care. It does not justify a consumer article telling readers that taking inositol will help them conceive. PCOS-related subfertility is multifactorial; assessment requires bloodwork, ultrasound, partner workup, and a treating clinician's plan.

If the goal is conception and inositol is being considered, the right move is a consultation with a reproductive endocrinologist rather than a supplement purchase. For broader prenatal-period nutrition, the prenatal supplements category for women covers folate, choline and the rest of the prenatal stack, and explicitly hands fertility-treatment decisions to a specialist. This is not fertility advice.

Inositol vs metformin — an honest head-to-head

Head-to-head RCTs that pit myo-inositol against metformin in PCOS do exist, and they tend to get quoted out of context. The clearest set: Raffone and colleagues, in 2010, randomised participants with PCOS to MI 4 g/day plus folic acid against metformin 1,500 mg/day over six months. They reported comparable gains in ovulation rates and metabolic markers among non-obese subjects, with notably fewer gastrointestinal adverse events on the inositol arm [raffone2010]. Fruzzetti and colleagues reached the same conclusion in 2017 in their 6-month comparison: MI came out non-inferior to metformin on HOMA-IR within the inclusion-criteria-defined population [fruzzetti2017].

The 2024 Monash review extends the same comparison and adds an important meta-analytic caveat: myo-inositol likely causes fewer gastrointestinal adverse events than metformin, but the certainty of evidence around efficacy equivalence stays in the low-to-very-low range. [monash2024]

The takeaway a careful reader should draw from this:

• Reasonable as a solo intervention: women presenting with mild-to-moderate PCOS, no diagnosed type-2 diabetes, no metformin prescription, no immediate fertility goal, and a clinician comfortable with a 12-week trial of supportive nutrition before reaching for prescription metabolic therapy.
• NOT a metformin replacement: women whose physician has prescribed metformin for overt insulin resistance, established type 2 diabetes, or anovulatory infertility under specialist care. Swapping metformin for inositol on the strength of a Reddit post is a category error.

Combined-therapy data (Le Donne 2019 and others) suggests inositol layered on top of metformin is generally additive on metabolic endpoints, with no specific drug interaction warning to flag. That call, again, is the prescribing physician's. Adding any supplement on top of a prescription drug for a diagnosed endocrine condition without discussing it with the prescriber is not a reasonable risk.

PCOS phenotypes (Rotterdam A/B/C/D) — who responds to inositol

The 2003 Rotterdam consensus, endorsed in revised form by the 2023 international guidelines, defines PCOS as needing two of three features: (1) oligo- or anovulation, (2) clinical or biochemical hyperandrogenism, (3) polycystic-appearing ovaries on ultrasound. That two-of-three rule generates four distinct phenotypes [rotterdam2004][teede2023]:

• Phenotype A: all three features. The "classic" PCOS picture; typically the most insulin-resistant; highest cardiometabolic risk across the lifespan.
• Phenotype B: anovulation plus hyperandrogenism, without polycystic ovaries visible on ultrasound. Metabolic profile is often similar to A.
• Phenotype C: hyperandrogenism plus polycystic ovaries, but with regular ovulation. Less metabolic disturbance on average.
• Phenotype D: anovulation plus polycystic ovaries, without hyperandrogenism. Generally the leanest and least insulin-resistant phenotype.

Inositol's metabolic mechanism, which corrects an insulin-signalling defect, predicts that the biggest effect would land in the most insulin-resistant phenotypes (A and B). The Wadhwa 2024 trial, published in Gynecologic and Obstetric Investigation, tested the MI + DCI 40:1 protocol specifically in Rotterdam Phenotype A patients and confirmed metabolic and hormonal gains over the trial period — corroborating the prediction that this phenotype is the most reliable responder [wadhwa2024]. For Phenotype D (anovulatory but not insulin-resistant), the mechanistic case for inositol is weaker, and the corresponding trial evidence is thinner.

A clinician's note that does not show up on most consumer pages: knowing your phenotype is genuinely useful. If you do not know it yet, a conversation with your endocrinologist or gynaecologist about which Rotterdam phenotype your labs and imaging point toward delivers a better return than the next supplement order.

How to take inositol — dosage, timing, and what to expect

The protocol that runs through most modern PCOS-inositol RCTs:

• 2 grams of myo-inositol plus 50 milligrams of D-chiro-inositol, twice daily (4 g MI plus 100 mg DCI per day total), maintaining the 40:1 ratio
• Split across morning and evening, with food
• Typical trial duration: 12 to 24 weeks before judging response
• Powder versus capsule forms are functionally equivalent; powder usually works out as the cheaper option at 4 g/day because the per-dose volume is fairly large
• For the myo-inositol-monotherapy variant from older trials (Gerli 2007, Costantino 2009): 2 g myo-inositol twice a day without added DCI, roughly equivalent on metabolic endpoints for non-obese PCOS [costantino2009]

Oral myo-inositol absorbs at roughly 90% in healthy women via sodium-dependent and sodium-independent transporters running along the small intestine; absorption may be slightly reduced in a subset of women with PCOS who carry intestinal transporter variants, but this is not something a consumer can act on.

Time to noticeable effect:

• Fasting insulin and HOMA-IR readings shift detectably from about week 8 onwards
• Menstrual cycle regularisation typically requires a minimum of three cycles
• Hirsutism and acne, when they shift at all, usually take six months or more before becoming visible
• Mood and energy: anecdotal and confounded; do not judge inositol on week-three energy levels

The single most common reason readers of PCOS forums report inositol "didn't work for me" is judging the response at the four-week mark. The trials that actually demonstrate effects ran for twelve to twenty-four weeks. Patience is part of the protocol.

Skipping a single dose now and again is unlikely to matter; missing several days running breaks the steady-state and tends to be the most common adherence pitfall. For women whose schedules involve travel or irregular days, the capsule form sidesteps the powder-and-mixing problem at the cost of swallowing several capsules per dose.

Side effects, contraindications and drug interactions

The safety record of inositol at PCOS doses is reassuring. The most common adverse effect across trials is mild gastrointestinal upset — nausea, flatulence, loose stools — at intake of 4 g per day or more, reported in roughly 10–15% of trial participants and broadly self-limiting plus dose-dependent. Headache turns up less often (under 5%). Dizziness is rare. Doses as high as 12 g per day have been examined in other indications (notably high-dose work in obsessive-compulsive disorder) without serious adverse events beyond GI symptoms.

The most under-discussed caution is bipolar disorder. Case reports plus a single small open-label series have raised the possibility that inositol at high doses may trigger manic episodes in patients diagnosed with bipolar I or bipolar II. Anyone with such a diagnosis should check in with their treating psychiatrist before adding inositol at the PCOS dose, even though those doses sit well below the high-dose OCD protocols that originally produced the signal.

Pregnancy. Myo-inositol has accumulated extensive study during pregnancy, including for gestational-diabetes prevention in at-risk pregnancies. In 2013, D'Anna and colleagues reported lower gestational-diabetes incidence with myo-inositol supplementation in women carrying a family history of type 2 diabetes, and at standard doses the supplement is widely regarded as safe [danna2013]. Women who fall pregnant while taking inositol should still talk through continuation with their OB-GYN, particularly if other supplements are being added or dropped at the same time. Breastfeeding data remain limited; default to a clinician conversation.

Drug interactions.

• Metformin: combined use has been examined and turns out broadly additive on metabolic endpoints, with no specific interaction warning — but the call to layer inositol on top of an active prescription belongs to the prescribing physician.
• Oral contraceptives: no documented direct pharmacokinetic interaction. Combined OCs control the menstrual cycle by hormonal mechanism and may mask inositol's downstream effects; whether adding inositol on top of an OC for PCOS is worth it warrants a gynaecologist conversation rather than self-management.
• Insulin or sulphonylureas: theoretical additive hypoglycaemic risk; blood-glucose monitoring is sensible if combining.
• Lithium and SSRIs: inositol at high doses (12 g) was historically explored in OCD research without clear SSRI interaction signals. At a PCOS dose of 4 g this is not really a practical concern, though anyone on lithium with a diagnosed mood disorder should still loop in their psychiatrist.

Long-term safety data extend to roughly 24 months of continuous use across PCOS trials, with no new signal showing up at 4 g/day. Beyond the two-year point the literature thins out — that is a coverage gap rather than an active concern.

The other PCOS supplements people ask about — NAC, spearmint tea, and the rest

Inositol owns the deepest PCOS evidence base of any dietary supplement, but it is not alone with serious data. Three names show up in nearly every PCOS supplement conversation; grading them honestly is worth the effort.

NAC for PCOS — moderate-but-noisier evidence

N-acetylcysteine (NAC) is a glutathione precursor with antioxidant and insulin-sensitising activity. In 2015, Thakker and colleagues published a systematic review in Obstetrics and Gynecology International that pooled eight RCTs; they found improved ovulation and pregnancy rates with NAC versus placebo in PCOS, although insulin-level changes themselves were less consistent across the included trials [thakker2015]. A 2025 systematic review in Nutrients by Pkhaladze and colleagues (PMC11768055) landed in roughly the same place: moderate effects on metabolic and reproductive endpoints in PCOS, with substantial trial-level heterogeneity in dose, duration and study population [pkhaladze2025]. Typical NAC trial doses run between 1.2 and 1.8 grams per day, split into divided doses.

Versus inositol, NAC has a smaller RCT base, more methodological heterogeneity, and a less mechanistically clean story specifically for PCOS. NAC is well-tolerated — mild GI at the higher dose end; a theoretical interaction with nitrates. Reasonable as an add-on therapy, or for women who do not tolerate inositol; not the stronger first choice on current evidence.

Spearmint tea PCOS — limited but real

Grant's 2010 trial in Phytotherapy Research was a randomised controlled study: 42 women with PCOS drank spearmint tea twice daily against a placebo herbal tea for 30 days. Free and total testosterone fell significantly in the spearmint arm; LH and FSH rose; self-rated hirsutism on the Dermatology Quality of Life Index improved, while the objective Ferriman-Gallwey score did not shift at 30 days [grant2010]. Both Grant himself and most clinicians since have flagged that a 30-day window is too short for visible hirsutism change; three to six months is the realistic timeline.

The protocol that has built up practitioner use is two cups (around 250 mL each) of strong-brewed spearmint tea per day, roughly the equivalent of about 5 g of dried leaf. Safety is excellent; mild GI and occasional reflux are about the only common complaints. The mechanism is not yet fully characterised; candidate explanations include androgen-receptor antagonism and 5α-reductase modulation.

For women with PCOS whose primary concern is hormonal acne, spearmint tea owns the cleanest single-RCT evidence on free testosterone. For broader coverage of supplements aimed at hormonal acne, see the beauty supplements category for women.

The other names — vitamin D, omega-3, berberine, alpha-lipoic acid

• Vitamin D deficiency runs common in PCOS; correction is reasonable but is replacement nutrition, not "PCOS treatment".
• Omega-3 (EPA/DHA) has moderate evidence for triglyceride and androgen modulation in PCOS — a safe adjunct.
• Berberine has emerging metabolic data comparable to metformin across some trials, but a tighter safety margin and more drug interactions than inositol; not a primary recommendation in a YMYL consumer article.
• Alpha-lipoic acid, chromium picolinate, magnesium, zinc, melatonin all have small trials in PCOS without earning primary article real estate.

How to choose a quality inositol supplement

A label-reading checklist worth more than any brand name:

• Explicit MI and DCI weights on the label, given in milligrams. "Proprietary inositol blend" is opaque by design; whatever is on the label may not match what is in the capsule.
• A 40:1 ratio for combination products (typically 2,000 mg MI + 50 mg DCI per dose). Other ratios are out there (3.6:1, 5:1) but carry less RCT support.
• Third-party testing. USP Verified, NSF Certified for Sport, or Informed-Choice marks indicate independent verification of label content. Inositol contamination is unusual, but verifying that what the product contains matches what the label claims is reasonable due diligence.
• No DCI-monotherapy products. As discussed, in IVF trials high-dose DCI alone actively worsened oocyte quality [carlomagno2011].
• Pure MI powder is fine if you want the older Gerli/Costantino protocol — 4 g MI/day, no added DCI — and it is the most cost-effective option at the full dose.

Folic acid (200–400 µg) and alpha-lipoic acid (600 mg) often get bundled into PCOS-targeted inositol products. Folic acid in that range is a reasonable baseline regardless; alpha-lipoic acid carries some adjuvant data and is generally safe.

Frequently asked questions

How long does it take for inositol to work for PCOS?

Fasting insulin and HOMA-IR shifts become detectable in trials at around 8 weeks. Menstrual-cycle regularisation generally takes a minimum of three cycles, and hirsutism or acne changes, when they happen, usually need six months or longer. Judging the response at four weeks is the single most common reason readers later report inositol "did not work"; the trial protocols actually followed women for twelve to twenty-four weeks.

Can I take inositol with metformin?

Combined use has been examined and runs broadly additive on metabolic endpoints, with no specific drug-interaction warning. The call to layer inositol on top of an active metformin prescription is the prescribing physician's judgement, not the patient's. Adding any supplement to a prescription drug for a diagnosed endocrine condition without that conversation is not a reasonable risk, even where the supplement itself is well-tolerated.

Will inositol help me lose weight with PCOS?

Not directly. Inositol can help insulin sensitivity, and a calorie deficit is easier to hold when insulin sensitivity is improved — but the supplement itself is not a weight-loss drug. The 2024 Monash systematic review found no clinically meaningful weight effect attributable to inositol alone. Modest weight changes in the trials almost always involved concurrent dietary counselling and exercise prescription as part of the protocol.

Should I take myo-inositol alone or the 40:1 myo-inositol / D-chiro-inositol blend?

Both protocols rest on real evidence. The 40:1 blend (2 g MI plus 50 mg DCI twice daily) is the more recently studied combination for the insulin-resistant PCOS phenotypes; pure myo-inositol at 4 g/day was the dose used in the older Gerli and Costantino trials and remains a fair option, particularly for leaner PCOS phenotypes. The combination matters more than the brand. Avoid D-chiro-inositol monotherapy at higher doses: the 2011 Carlomagno paper documented worsened oocyte quality at DCI doses near 1,200 mg/day or above.

Is inositol safe while trying to conceive?

This is the question most often asked and least well-suited to a supplement article answering in absolute terms. Inositol has been investigated in IVF settings under reproductive-endocrinologist supervision, with generally favourable signals on oocyte quality, but PCOS-related subfertility is multifactorial and self-managing fertility on supplements is not the right approach. The actionable next step is a consultation with a reproductive endocrinologist who can review your bloodwork, imaging and partner workup. This is not fertility advice.

Does NAC work better than inositol for PCOS?

Not on the current data. NAC has a smaller and more heterogeneous RCT base; the 2015 Thakker meta-analysis flagged improved ovulation and pregnancy rates with NAC, but insulin-level effects were less consistent. NAC is a reasonable adjunct or alternative for women who do not tolerate inositol — but it is not the stronger first choice on the data we have today.

Does spearmint tea actually help PCOS hirsutism and acne?

Grant's 2010 randomised controlled trial in Phytotherapy Research recorded significant reductions in free as well as total testosterone over 30 days on two cups of spearmint tea daily, alongside rises in LH and FSH. Self-rated hirsutism improved; objectively scored hirsutism did not shift at 30 days — consistent with the well-established fact that visible hair changes lag biochemical androgen changes by months. For hormonal acne and hirsutism specifically, spearmint tea owns the cleanest single-trial evidence on free testosterone among the PCOS herbal options.

What are the side effects of inositol at 4 g per day?

Mild gastrointestinal upset (nausea, flatulence, loose stools) in roughly 10–15% of trial participants, generally self-limiting and dose-dependent. Headache under 5% and dizziness rare. The most under-discussed caution is bipolar disorder; case reports describe possible manic-episode triggers at the highest doses, so anyone with a diagnosed bipolar I or bipolar II disorder should bring inositol up with their psychiatrist before starting.

The bottom line on inositol for PCOS

At 2 grams of myo-inositol plus 50 milligrams of D-chiro-inositol twice daily, on the 40:1 ratio that mirrors healthy plasma physiology, inositol owns the deepest randomised-trial base of any dietary supplement tested in PCOS. Its strongest signal is on insulin sensitivity and HOMA-IR over a 12-to-24-week window, with smaller signals on menstrual regularity and androgens, and effectively no room in a consumer article for fertility-outcome promises. The 2024 update of the international PCOS guidelines grades overall certainty of evidence as low to very low; inositol fits the supportive nutrition adjunct label — not endocrine therapy, and not a metformin replacement when metformin is clinically indicated. Patients in Rotterdam Phenotype A or B (the most insulin-resistant phenotypes) are the likeliest responders; anyone already on metformin or oral contraceptives, or actively trying to conceive, should take any addition decision to their treating clinician rather than make it alone. For the broader category context this article sits inside the PCOS supplement category for women and links upward to the women's hormonal-balance supplement guide.

Sources

• [baillargeon2006] Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. (2006). Uncoupling between insulin and release of a D-chiro-inositol containing inositolphosphoglycan mediator of insulin action in obese women with PCOS. Metab Syndr Relat Disord 4(4):319–324.
• [carlomagno2011] Carlomagno G, Unfer V, Roseff S. (2011). The D-chiro-inositol paradox in the ovary. Fertility and Sterility 95(8):2515–2516.
• [costantino2009] Costantino D, Minozzi G, Minozzi E, Guaraldi C. (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. European Review for Medical and Pharmacological Sciences 13(2):105–110.
• [danna2013] D'Anna R, Scilipoti A, Giordano D, et al. (2013). Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care 36(4):854–857.
• [fruzzetti2017] Fruzzetti F, Perini D, Russo M, et al. (2017). Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecological Endocrinology 33(1):39–42.
• [grant2010] Grant P. (2010). Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytotherapy Research 24(2):186–188. PMID 19585478.
• [greff2023] Greff D, Juhász AE, Váncsa S, et al. (2023). Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology 21:10.
• [monash2024] Fitz V, Graca S, Mahalingaiah S, et al. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Journal of Clinical Endocrinology & Metabolism 109(6):1630–1655. PMC11099481.
• [nordio2012] Nordio M, Proietti E. (2012). The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. European Review for Medical and Pharmacological Sciences 16(5):575–581.
• [pkhaladze2025] Pkhaladze L, et al. (2025). Efficacy of N-Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. Nutrients 17(2):284. PMC11768055.
• [raffone2010] Raffone E, Rizzo P, Benedetto V. (2010). Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecological Endocrinology 26(4):275–280.
• [rotterdam2004] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 19(1):41–47.
• [showell2012] Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. (2012/2018). Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews.
• [teede2023] Teede HJ, Tay CT, Laven JJE, et al. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 120(4):767–793.
• [thakker2015] Thakker D, Raval A, Patel I, Walia R. (2015). N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstetrics and Gynecology International 2015:817849.
• [unfer2014] Unfer V, Carlomagno G, Dante G, Facchinetti F. (2014). Effects of myo-inositol in women with polycystic ovary syndrome: a systematic review of randomized controlled trials. Gynecological Endocrinology 28(7):509–515 (and supporting Reproductive BioMedicine Online comparison of MI:DCI ratios).
• [unfer2017] Unfer V, Facchinetti F, Orrù B, et al. (2017). Myo-inositol effects in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Endocrine Connections 6(8):647–658. PMID 29042448.
• [wadhwa2024] Wadhwa L, et al. (2024). The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria. Gynecologic and Obstetric Investigation 89(2):131. PMC11126204.

Reviewed by the HealthyHerbology editorial team. Last updated: 2026-05-24.